ClinicalTrials.gg
TerminatedNCT05319509Updated Nov 12, 2026

Pilot Study of Virtual Reality Therapy for Students With Anxiety

An interventional study of gameChange in Anxiety, sponsored by The University of Texas Health Science Center, Houston. Terminated at 1 site in United States. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
funding issues
Updated Nov 12, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

The purpose of this study is to assess changes in self-reported anxiety over the course of six virtual reality (VR) sessions and to assess changes in academic self-efficacy, as well as examine the feasibility and acceptability of a relatively short and time intensive VR intervention (i.e.,six sessions over the course of three weeks) for reducing anxiety symptoms in college students.

02

Conditions studied

  • Anxiety

Browse trials for

Keywords

  • virtual reality
  • college students
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's enrollment of 10 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 214 are open to participants now.

Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • enrolled in The University of Texas Health Science Center School of Public Health San Antonio regional campus
  • competent in English
  • total score of at least 3 on the Generalized Anxiety Disorder (GAD-2)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving psychological treatment for anxiety symptoms, or has received treatment in the last year.
  • Report photosensitive epilepsy.
  • Report stereoscopic vision or balance problems
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    gameChange

    Device: gameChange

Interventions

  • DevicegameChange

    Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.

06

What researchers measure

Primary outcomes

  1. Change in state anxiety as assessed by the Liebowitz Social Anxiety Scale-Self Report version (LSAS-SR)

    The LSAS-SR questionnaire is composed of 24 items divided into 2 subscales, 13 concerning performance anxiety, and 11 pertaining to social situations. The 24 items are first rated on a Likert Scale from 0(none) to 3(severe) on fear felt during the situations, and then the same items are rated from 0(never)-3(usually)regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points. Score of 30 or less indicates social anxiety disorder(SAD) is unlikely, score of 30-60 shows that SAD is probable and score 60-90 indicates that SAD is highly probable.

    Time frame: before first session in week 1, before third session in week 2 and before sixth session in week 3

  2. Change in depressive symptoms as assessed by score on the Patient Health Questionnaire-4 (PHQ-4)

    The PHQ-4 questionnaire consists of 4 questions and each is rated on a 4 point scale from 0(not at all) to 3(every day) for a maximum score of 12,a higher number indicating a worse outcome.

    Time frame: Baseline(before the first session in week 1)

  3. Change in anxiety related behaviors such as rate of speech

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  4. Change in anxiety related behaviors such as volume of speech

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  5. Change in anxiety related behaviors such as Negative self-talk

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  6. Change in anxiety related behaviors such as Utterances about experience

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  7. Change in anxiety related behaviors such as Laughter

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  8. Change in Psychomotor agitation such as pacing

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  9. Change in Psychomotor agitation such as Fidgeting

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  10. Change in Psychomotor agitation such as Rubbing hands/neck/head

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

  11. Change in physiology such as perspiration

    Anxiety-related behaviors will be recorded using an event sampling observation guide

    Time frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)

Secondary outcomes

  1. Change in self-reported academic performance as assessed by the Motivated Strategies for Learning Questionnaire (MSLQ)

    The MSLQ questionnaire consists of 9 questions each one is scored from 1= not at all true of me to 7=very true of me, a higher number indicating a better outcome with a maximum score of 63

    Time frame: before first session in week 1, before third session in week 2 and before sixth session in week 3

  2. change in feasibility as assessed by the rating on a short questionnaire

    The usability questionnaire is developed by gameChange about the ease of VR software use, believability of VR environment, and level of engagement. this consists of 5 questions and each one is scored form 1(very difficult) to 5(very easy) for a maximum score of 25, a higher number indicating more easiness in using the VR software

    Time frame: after the third session in week 2 , after sixth session in week 3

  3. Change in acceptability as assessed by the rating on a short questionnaire

    The usability questionnaire is developed by gameChange about the ease of VR software use, believability of VR environment, and level of engagement. this consists of 5 questions and each is scored form 1(strongly disagree) to 5(strongly agree) for a maximum score of 25

    Time frame: after the third session in week 2 , after sixth session in week 3

  4. Change in perceived presence in the virtual environment (as indicated by continuous score on the Igroup Presence Questionnaire (IPQ)

    There are 14 questions and each one is scored form -3 to +3. A total negative score indicates that the participant personally felt very disconnected from VR world, and that they lacked believable presence within world, and rather felt like they were manipulating a machine from an outside perspective.

    Time frame: after the third session in week 2 and the sixth session in week 3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2022 to primary completion in Sep 2026, 53 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Apr 2027 → Sep 2026 and completion Aug 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 8, 2022
StartActual
Apr 1, 2022
Primary completionActual
Sep 21, 2026was Apr 2027
CompletionActual
Sep 21, 2026was Aug 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated funding issues
changed Nov 12, 2026
Primary completion
Apr 1, 2027→Sep 21, 2026 (actual)
Nov 12, 2026
Study completion
Aug 1, 2027→Sep 21, 2026 (actual)
Nov 12, 2026
Enrollment
100 (estimated)→10 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Terminated
    Why stopped funding issues
    Primary completion Apr 1, 2027→Sep 21, 2026 (now actual)
    Study completion Aug 1, 2027→Sep 21, 2026 (now actual)
    Enrollment 100 (estimated)→10 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05319509
Responsible party
Jack Tsai (Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Apr 8, 2022
Start date
Apr 1, 2022
Primary completion
Sep 21, 2026
Completion
Sep 21, 2026
Last update
Nov 12, 2026

Study contacts

Tsai Jack, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion